公开(公告)号：US20180273532A1

公开(公告)日：2018-09-27

申请号：US15841767

申请日：2017-12-14

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Roch Boivin ,  Eric Carlson ,  Atsushi Endo ,  Hans Hansen ,  Lynn D. Hawkins ,  Sally Ishizaka ,  Matthew Mackey ,  Sridhar Narayan ,  Takashi Satoh ,  Shawn Schiller

IPC: C07D471/04 ,  A61K31/55 ,  C07D487/04 ,  A61K31/519

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  Y02P20/582

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

公开(公告)号：US09850242B2

公开(公告)日：2017-12-26

申请号：US15233520

申请日：2016-08-10

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Roch Boivin ,  Eric Carlson ,  Atsushi Endo ,  Hans Hansen ,  Lynn D. Hawkins ,  Sally Ishizaka ,  Matthew Mackey ,  Sridhar Narayan ,  Takashi Satoh ,  Shawn Schiller

IPC: A01N43/90 ,  A61K31/519 ,  C07D471/04 ,  C07D487/04 ,  A61K31/55

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  Y02P20/582

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

公开(公告)号：US20160339032A1

公开(公告)日：2016-11-24

申请号：US15233520

申请日：2016-08-10

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Roch Boivin ,  Eric Carlson ,  Atsushi Endo ,  Hans Hansen ,  Lynn D. Hawkins ,  Sally Ishizaka ,  Matthew Mackey ,  Sridhar Narayan ,  Takashi Satoh ,  Shawn Schiller

IPC: A61K31/519 ,  A61K31/55

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  Y02P20/582

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis

公开(公告)号：US09446046B2

公开(公告)日：2016-09-20

申请号：US14806174

申请日：2015-07-22

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Roch Boivin ,  Eric Carlson ,  Atsushi Endo ,  Hans Hansen ,  Lynn D. Hawkins ,  Sally Ishizaka ,  Matthew Mackey ,  Sridhar Narayan ,  Takashi Satoh ,  Shawn Schiller

IPC: A01N43/90 ,  A61K31/519 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  Y02P20/582

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

公开(公告)号：US11130758B2

公开(公告)日：2021-09-28

申请号：US16845594

申请日：2020-04-10

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Roch Boivin ,  Eric Carlson ,  Atsushi Endo ,  Hans Hansen ,  Lynn D. Hawkins ,  Sally Ishizaka ,  Matthew Mackey ,  Sridhar Narayan ,  Takashi Satoh ,  Shawn Schiller

IPC: C07D487/04 ,  C07D471/04 ,  A61K31/519 ,  A61K31/55

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

公开(公告)号：US20160030430A1

公开(公告)日：2016-02-04

申请号：US14806174

申请日：2015-07-22

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Roch Boivin ,  Eric Carlson ,  Atsushi Endo ,  Hans Hansen ,  Lynn D. Hawkins ,  Sally Ishizaka ,  Matthew Mackey ,  Sridhar Narayan ,  Takashi Satoh ,  Shawn Schiller

IPC: A61K31/519

CPC classification number: C07D471/04 ,  A61K31/519 ,  A61K31/55 ,  C07D487/04 ,  Y02P20/582

Abstract: Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis

公开(公告)号：US20140065100A1

公开(公告)日：2014-03-06

申请号：US14075130

申请日：2013-11-08

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Daniel P. Rossignol ,  Sally T. Ishizaka ,  Lynn D. Hawkins ,  Scott Fields

IPC: A61K39/00 ,  A61K45/06

CPC classification number: A61K39/0011 ,  A61K45/06 ,  A61K2039/55511

Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

Abstract translation: 本发明涉及免疫治疗化合物以及用于在患有癌症，癌症诊断，癌症治疗或癌症治疗后恢复的危险中的受试个体中刺激免疫应答的方法或本发明的化合物可以是 作为对个体进行预防以预防或延缓癌症的发展。